Current progress and future perspectives in the development of anti-polo-like kinase 1 therapeutic agents.
Current progress and future perspectives in the development of anti-polo-like kinase 1 therapeutic agents.
复制标题
DOI：
10.12688/f1000research.11398.1
复制
发表时间：
2017
期刊：
影响因子：
--
通讯作者：
Lee KS
中科院分区：
文献类型：
--
作者：
Park JE;Hymel D;Burke TR Jr;Lee KS
虽然显着水平的副作用往往与它们的使用，微管导向剂，主要针对快速生长的有丝分裂细胞已被认为是一些最有效的抗癌治疗。为了开发新一代具有减少副作用和增强肿瘤特异性的抗有丝分裂药物，研究人员已经瞄准了有丝分裂进展所需的各种蛋白质。Polo样激酶1（Plk1）作为有丝分裂的重要靶点，在抗癌药物的研究中受到广泛关注。迄今为止，已经开发了多种抗Plk 1药物，其中几种目前正在进行临床试验。在这里，我们将讨论产生抗Plk 1药物的现状以及未来设计和开发更有效的抗Plk 1治疗药物的策略。
Although significant levels of side effects are often associated with their use, microtubule-directed agents that primarily target fast-growing mitotic cells have been considered to be some of the most effective anti-cancer therapeutics. With the hope of developing new-generation anti-mitotic agents with reduced side effects and enhanced tumor specificity, researchers have targeted various proteins whose functions are critically required for mitotic progression. As one of the highly attractive mitotic targets, polo-like kinase 1 (Plk1) has been the subject of an extensive effort for anti-cancer drug discovery. To date, a variety of anti-Plk1 agents have been developed, and several of them are presently in clinical trials. Here, we will discuss the current status of generating anti-Plk1 agents as well as future strategies for designing and developing more efficacious anti-Plk1 therapeutics.